ACTUATE THERAPEUTICS

Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas

17 Jul 2025 05:45:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial

24 Jun 2025 06:15:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

20 Jun 2025 05:45:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

16 Jun 2025 05:30:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

02 Jun 2025 06:00:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

31 May 2025 13:30:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

22 May 2025 14:05:00 By Nasdaq GlobeNewswire

Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting

07 May 2025 05:00:01 By Nasdaq GlobeNewswire

Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer

06 May 2025 05:00:01 By Nasdaq GlobeNewswire

Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025

30 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

23 Apr 2025 07:24:10 By Nasdaq GlobeNewswire

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

17 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer

25 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

06 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer

07 Jan 2025 05:00:01 By Nasdaq GlobeNewswire

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

17 Dec 2024 05:28:17 By Nasdaq GlobeNewswire

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

17 Dec 2024 05:00:00 By Nasdaq GlobeNewswire

Actuate Therapeutics to be Added to Russell 2000® Index

26 Nov 2024 05:00:00 By Nasdaq GlobeNewswire

Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma

12 Nov 2024 05:00:03 By Nasdaq GlobeNewswire

Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development

29 Oct 2024 15:39:24 By Nasdaq GlobeNewswire